Eton Pharmaceuticals Reports Q1 2025 Revenue Surge of 76%, Achieves Non-GAAP EPS of $0.07 Despite GAAP EPS Loss of $(0.06)

Reuters
05-14
Eton Pharmaceuticals Reports Q1 2025 Revenue Surge of 76%, Achieves Non-GAAP EPS of $0.07 Despite GAAP EPS Loss of $(0.06)

Eton Pharmaceuticals Inc. reported its financial results for the first quarter of 2025, highlighting significant growth in product sales and revenues. The company achieved Q1 2025 revenue of $17.3 million, with product sales accounting for $14.0 million. This represents a 76% increase over the same period in 2024 and marks the 17th consecutive quarter of sequential product sales growth. The growth was primarily driven by the momentum of ALKINDI SPRINKLE® and the recent acquisition of INCRELEX®, which was relaunched in the U.S. in late December. Eton also reported an adjusted EBITDA of $3.7 million for the quarter. The company's cash position as of March 31, 2025, was $17.4 million, with $2.1 million generated in operating cash flow during the quarter. A pivotal clinical study for product candidate ET-600 yielded positive results, and the company submitted a New Drug Application to the U.S. FDA. Additionally, Eton established a Wilson disease franchise with the acquisition and relaunch of GALZIN® capsules and introduced product candidate ET-700. Eton Pharmaceuticals continues to focus on developing treatments for rare diseases, with management expressing confidence in ongoing growth throughout 2025 and beyond.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450439-en) on May 13, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10